Singapore, June 17 -- US based Neurocrine Biosciences, Inc. and Japanese firm Takeda Pharmaceutical Company Limited have announced a strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline.

Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.

Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration.

Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development miles...